Ignite Creation Date:
2024-05-05 @ 11:31 AM
Last Modification Date:
2024-10-26 @ 9:08 AM
Study NCT ID:
NCT00061633
Status:
COMPLETED
Last Update Posted:
2019-01-16
First Post:
2003-05-30
Brief Title:
Phase 2 Trial of TD 6424 Telavancin Versus Standard Therapy for Complicated Gram Positive Skin and Skin Structure Infections Gram Positive cSSSI
Sponsor:
Cumberland Pharmaceuticals
Organization:
Cumberland Pharmaceuticals
Study Overview
Official Title:
A Phase 2 Randomized Double-Blind Multinational Trial of Intravenous Telavancin Versus Standard Therapy for Treatment of Complicated Gram Positive Skin and Skin Structure Infections Gram Positive cSSSI
Status:
COMPLETED
Status Verified Date:
2019-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
FAST
Brief Summary:
Serious infections caused by resistant bacteria are becoming more of a medical problem throughout the world One of the ways to deal with this problem is to develop new drugs that can control these bacteria This study will measure how well TD-6424 Telavancin can control infections and whether this drug can be safely given to patients
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None